Clinical Trial

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) in participants with cystic fibrosis (CF).
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2023-04-24; most recent amendment 2026-04-23.
Status change: Not Yet Recruiting → Enrolling by Invitation 2023-08-25
Trial Details
NCT Number NCT05844449
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Cystic Fibrosis
Enrollment 174 participants
Start Date 2023-08-11
Primary Completion 2029-07-30 (estimated)
Study Completion 2029-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-29